Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
03 Gennaio 2025 - 2:00PM
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that
the Company will present at the 43rd Annual J.P. Morgan Healthcare
Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The
presentation will be webcast live and can be accessed here or by
visiting Madrigal’s Investor Relations Site, Events and
Presentations.
About Madrigal Madrigal Pharmaceuticals, Inc.
(Nasdaq: MDGL) is a biopharmaceutical company focused on delivering
novel therapeutics for metabolic dysfunction-associated
steatohepatitis (MASH), a liver disease with high unmet medical
need. Madrigal’s medication, Rezdiffra (resmetirom), is a
once-daily, oral, liver-directed THR-β agonist designed to target
key underlying causes of MASH. For more information, visit
www.madrigalpharma.com.
Investor ContactTina Ventura,
IR@madrigalpharma.com
Media ContactChristopher
Frates, media@madrigalpharma.com
Grafico Azioni Madrigal Pharmaceuticals (NASDAQ:MDGL)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Madrigal Pharmaceuticals (NASDAQ:MDGL)
Storico
Da Mar 2024 a Mar 2025
